Compositions and methods for controlling phytopathogenic infections
AssigneesInstitut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement (Inrae), AGROCAMPUS OUEST (Institut national supérieur des sciences agronomiques, agro-alimentaires,, Universite D'Angers
InventorsNelly BATAILLÉ-SIMONEAU, Thomas CHARPENTIER, Thomas GUILLEMETTE, Anne-Marie LE RAY, Pascal RICHOMME-PENIGUEL, Philippe SIMONEAU, Guillaume VIAULT
Life of this patent
Estimating the term…
Abstract
A phytopharmaceutical method for treating a plant organ affected by a phytopathogenic fungal strain. The method includes the steps of applying on the plant organ a composition including at least one xanthone UPR (Unfolded Protein Response) inhibitor, preferably, an IRE-1 (Inositol-Requiring Enzyme 1) inhibitor, in a sub-effective amount. Also, a phytopharmaceutical composition including at least one UPR (Unfolded Protein Response) inhibitor in a sub-effective amount.
Claims21
1-15. (canceled)
A method for preventing, controlling or treating a fungal infection by a phytopathogenic fungal strain on a plant organ, said method comprising the steps of applying on the plant organ a composition comprising at least one UPR (Unfolded Protein Response) inhibitor, in an in vitro sub-effective concentration being a concentration equal or inferior to a non-fungicidal concentration C1 of said inhibitor against the phytopathogenic fungal strain:
- wherein the non-fungicidal concentration C1 is determined by comparing the growth of the phytopathogenic fungal strain cultures in contact with increasing concentrations of said at least one UPR inhibitor, with the growth of a control culture of the phytopathogenic fungal strain, in the absence of said at least one UPR inhibitor;
- the last concentration of the increasing concentrations of the at least one UPR inhibitor resulting in the same fungal culture growth as the control culture being retained as the non-fungicidal concentration C1 of said at least one UPR inhibitor;
- wherein the at least one UPR inhibitor is at least one xanthone of formula I:
- wherein:
- R2=R8:
- prenyl, R1=R3=R6=R7:
- OH, and R4=R5:
- H (γ-mangostin);
- R1=R3=R5:
- OH, R2=R6=R7=R8:
- H, and R4:
- prenyl (1,3,5 trihydroxy-4-prenylxanthone);
- R1=R3=R5:
- OH, R4=R6=R7=R8:
- H, and R2:
- prenyl (1,3,5 trihydroxy-2-prenylxanthone);
- R1=R5=R6:
- OH, R2=R3=R4=R8:
- H, and R7:
- prenyl;
- R8:
- geranyl, R1=R3=R6=R7:
- OH, and R4=R5:
- H (demethylrubraxanthone);
- and
- R1=R3=R4=R5:
- OH, R6=R7=R8:
- H, and R2:
- prenyl, wherein the R2 and R3 moieties form a 2,3,3-trimethyltetrahydrofuran ring,
- wherein the compound of formula (I) inhibits the UPR cellular development and environmental adaptation in the phytopathogenic fungal strain, once they have been exposed to the plant defense molecules expressed by the plant organ.
A phytopharmaceutical composition against a phytopathogenic fungal strain comprising at least one UPR (Unfolded Protein Response) inhibitor in a sub-effective amount, said at least one UPR inhibitor being selected from the group consisting of γ-mangostin, 1,3,5 trihydroxy-4-prenylxanthone, 1,3,5 trihydroxy-2-prenylxanthone and a mixture thereof;
- said sub-effective amount being a concentration ranging from 5 μM to 500 μM in association with at least one phytopharmaceutical vehicle.
Dependencies are inferred from the claim text.